CML Advocates Network

advocates
Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).

Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)

Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.

Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.

Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec

COVID-19
(Also called Coronavirus or SARS-Cov 2) An infectious disease caused by a newly discovered coronavirus in 2019. Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness.

BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Chronic
Long-lasting, slowly developping

Acute
Of sudden onset, severe; of short duration.

CLL
Chronic lymphocytic leukemia

Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.

CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

ASH
American Society of Hematology

MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)

CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

TFR
Abbreviation for Treatment-Free Remission. In CML is referred to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment after having been in deep molecular residual disease over a longer period of time.

About Leukemia Patient Advocates Foundation
The Leukemia Patient Advocates Foundation is a patient-led non-profit foundation in Switzerland. Its mission is to improve the lives & survival of patients affected by Leukemia. It is a platform for discussions & best practice sharing to Leukemia patient groups worldwide. The foundation collaborates with all stakeholders involved in research, policy, treatment and care. It also acts as a platform for patient organisations – concentrating on educating, connecting and supporting patient group leaders.

The foundation acts as a legal platform for self-sustained patient advocacy networks: The CML Advocates Network (128 patient organisations in 93 countries), the MPN Advocates Network, the CLLAdvocates Network and the Acute Leukemia Advocates Network (ALAN).

Vision and Mission of the Leukemia Patient Advocates Foundation

Our vision is a world in which all leukemia patients have access to the best treatment, care and support available.

Our mission is:
- To improve the lives and survival rates of patients affected by leukemia, as well as their relatives, worldwide
- To support patient leaders in providing help and support to leukemia patients and their relatives
- To provide a platform for education and best practice sharing of leukemia patient groups worldwide
- To collaborate with other stakeholders involved in research, treatment and care of leukemia patients
The Leukemia Patient Advocates Foundation hosts the global CML Advocates Network, MPN Advocates Network, CLLAdvocates Network and the last one, the Acute Leukemia Advocates Network (ALAN).

CML Advocates Network

Hosted by the Leukemia Patient Advocates Foundation, the global "CML Advocates Network" (https://cmladvocates.net) connects 128 patient organisations in 93 countries on all continents. The CML Advocates Network is a worldwide network designed and run by CML patients and carers who are registered patient group advocates and organisers.

The Leukemia Patient Advocates Foundation hosts the "CML Horizons" conference as the annual global leadership meeting that welcomes patient leaders from all world regions (https://www.cmladvocates.net/cmlhorizons). An elected "CML Horizons Steering Committee", as a steering committee (as defined in the foundation's statutes) within the Leukemia Patient Advocates Foundation, carries all responsibility to run the "CML Horizons" conferences. Following elections by the worldwide CML community in May 2019, the CML Horizons Steering Committee consists of the following nine members of which six are CML patients themselves, and which represent all major regions of the world.
- Felice Bombaci (Italy, Western Europe region representative; Co-chairman of the CML Advocates Network)
- Sarunas Narbutas (Lithuania, Central and Eastern Europe & West Asia region representative; Co-chairman of the CML Advocates Network)
- Giora Sharf (Israel, co-founder of the CML Advocates Network)
- Jan Geissler (Germany, co-founder of the CML Advocates Network)
- Jana Pelouchová (Czech Republic, Co-founder of the CML Advocates Network)
- Bahija Gouimi (Morocco, Middle East & Africa region representative)
- Lisa Machado (Canada, North America region representative; Treasurer of the CML Advocates Network)
- José Castro (Costa Rica, Latin America region representative)
- Rod Padua (Philippines, Asia-Pacific region representative)
The management is supported by the Executive Director, Denis Costello with our Head of Communications and Programme Manager Celia Marín celia@cmladvocates.net and the Programme Manager Lidija Pecova lidija@cmladvocates.net

MPN Advocates Network

Hosted by the Leukemia Patient Advocates Foundation, the global "MPN Advocates Network" (https://www.mpn-advocates.net) was founded by representatives from the Netherlands, Spain and the UK. The MPN Advocates Network's immediate goal is to increase the international scope of the organisation by contacting MPN patient groups in other countries and inviting them to become part of the network. The initial focus will be groups in Europe, but the intention is to be a worldwide organisation.

The MPN Advocates Network hosts the "MPN Horizons", the international conference for MPN patient advocacy leaders, works on educating patient advocates, building patient groups’ capacity, implementing advocacy initiatives with a real impact in the countries and finally enforcing cooperation in the global “MPN Advocates Network”.

A Steering Committee within the Leukemia Patient Advocates Foundation carries all responsibility to run the MPN Advocates Network. The members of the Steering Committee are:
- Chairperson: Jon Mathias, London UK
- Vice Chairperson: Peter Loffelhardt, Barcelona/Switzerland
- Secretary/Treasurer: Cheryl Petruk, Canada
- Giora Sharf, LePaf Representative, Israel
- Felice Bombaci, Italy
- Lexi Moore & Michelle Woehrle , USA
- Mirjana Babamova, Macedonia
- Robi Zelig, Israel
- Werner Zinkand, Germany
Giora Sharf (Israel), as a trustee of the Leukemia Patient Advocates Foundation, supervises the finances of the MPN Advocates Network and its compliance with Swiss Regulatory requirements regarding the non-profit status.

For more information, please visit the MPN Advocates Network website

CLL Advocates Network

Hosted by the Leukemia Patient Advocates Foundation, the establishment of the CLLAdvocates Network (CLLAN) (https://www.clladvocates.net) and commencement of the new network’s activities aims to ensure the successes seen in CML are replicated for CLLand common goals are shared. The CLLAdvocates Network (CLLAN) was founded by representatives from Canada, Czech Republic, France, Israel, Portugal, UK and the United States. The CLLAdvocates Network Steering Committee consists of the following 8 members, of which 3 are CLLpatients and one a carer. The other members are CLLpatient advocates:
- Nick York, UK - Interim Chair
- Pierre Aumont, France - Vice-Chair
- Jana Pelouchova, LePAF Rep, Czech Rep. - Treasurer
- Michael Rynne, Ireland - Communications Officer
- Felice Bombaci, Italy
- Brian Koffman, United States of America
- Deborah Baker, Canada
The CLLAdvocates Network’s immediate goals include connecting across the globe with CLLpatient groups, CLLpatient advocates and patient organisations supporting blood cancer patients including CLL.

The CLLAdvocates Network hosts the "CLLHorizons", a unique opportunity for CLLpatient organization representatives to meet and network, giving them the opportunity to discuss issues facing CLLpatients and hopefully start to think about what they could do better to help CLLpatients in their communities.

Acute Leukemia Advocates Network (ALAN)

The newest patient advocates network within the Leukemia Patient Advocates Foundation is the Acute Leukemia Advocates Network (ALAN) (https://acuteleuk.org).

The ALAN is an independent global network of patient organisations representatives and patient organisations, dedicated to
- changing outcomes of patients with acute leukemias by strengthening patient advocacy in that area by developing patient information and specific support for patients with acute leukemias and their carers in all countries;
- strengthening patient organisations by sharing best practices and providing toolkits in patient advocacy;
- creating awareness about acute leukemias and how to better support leukemia patients; advocating for better treatment, care & access to healthcare services;
- improving education for healthcare professionals serving leukemia patients as well as collaborating with other initiatives and stakeholders with similar goals.
Similar to the CML Advocates Network, MPN Advocates Network and CLLAdvocates Network within the LePAF, the ALAN is not a network mainly targeting (english-language) patients and carers directly, but acts as a “network of organisations”. It aims to build capacity in the members of the network to deliver tailored services to acute leukemia patients and carers on the national level, while joining forces between organisations on the policy and research level across countries.

The first ALAN Steering Committee consists of the following patient advocates:
- Zack Pemberton-Whiteley, Chair (UK)
- Anita Waldmann (Germany)
- Sophie Wintrich (UK)
- Jan Geissler (Leukemia Patient Advocates Foundation representative)
Board of the Leukemia Patient Advocates Foundation

The foundation's statutes mandate the foundation board only with supervisory and financial management roles, while its statutory committees, as listed above, are fully self-governed, autonomous initiatives. Projects are run by the committees, not by the foundation board. Formally, the Leukemia Patient Advocates Foundation is represented by the following trustees of the Foundation:
- Jana Pelouchová (President, Czech Republic)
- Jan Geißler (Vice President and Managing Director, Germany)
- Giora Sharf (Treasurer, Israel)
- Erik Aerts (Board Member, Switzerland)
Registered Address & Contact Details

We are purely patient-run, non-profit and public interest, and we have no legal department. Talking to each other first is always the best solution. If you see a challenge for whatever reason, please contact us directly - we are very confident any issue can be solved.

Leukemia Patient Advocates Foundation
P.O.B. 453
CH-3000 Bern 7
Switzerland
Registration: Chamber of Commerce of Canton Bern, Switzerland – CH-036.7.052.001-2

Written correspondence is preferred to be sent to the following address:

LeukaNET e.V.
Am Rothenanger 1b
85521 Riemerling
Germany
Email: info@cmladvocates.net

Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
About the Network
The CML Advocates Network Story

The CML Advocates Network is an active network specifically for leaders of Chronic Myeloid Leukemia (CML) patient groups, connecting 128 patient organisations in 93 countries on all continents. It was set-up and is run by CML patients and carers. Its aim is to facilitate and support best practice sharing among patient advocates across the world.

The idea to form the CML Advocates Networkwas first discussed in 2005 during the 4th International "New Horizons in Cancer" conference in Dublin for CML & GIST patient advocacy groups. Since their initiation in 2002, the "New Horizons" annual conferences have become a key networking event and a platform for best practice and knowledge sharing for CML and GIST patient groups from all five continents. Presentations by expert clinicians, medical professionals and patient group organizers enable the sharing of the most up to date clinical information, of best practice in patient advocacy as well as of hands-on experience, e.g. and on how to run patient advocacy organisations. The CML Advocates Networkwebsite was then set up in 2007 to keep the international networking going also after the annual meetings, as well as to bridge geographical distances between patient leaders.

The network was initiated by four patient groups from Germany, UK, Czech Republic and Israel, facilitated by an unrestricted grant from Novartis. It is run independently by CML patients and hosted by the patient-run Leukemia Patient Advocates Foundation. The website has turned out to be a very powerful tool to support patient leaders around the world, to provide a knowledge base on CML advocacy, and to facilitate best practice sharing.

We welcome members from all CML patient group organizations throughout the world to become part of the CML Advocates Network!

Our Objectives

The four main objectives of the CML Advocates Network are:
- To provide a worldwide web directory of CML patient groups, to allow patient groups to find national support groups in another country. Check our list of members HERE.
- To provide a platform for communication for CML patient advocates by sharing best practices on cancer patient advocacy, e.g. on the occasion of World CML Day.
- To build a CML-specific, patient-friendly knowledge base (CML glossary, Ressource and Knowledge Center on generics, Clinical Trials Database, patient-friendly summaries of ELN-recommendations in multiple languages, and others)
- To provide an area where educational material is ready for download to patient advocates.
The website does not intend to be a platform for public discussions. Hence interactive functionality is mainly being offered in a non-public, member-only area which is accessible by registered representatives of leukemia patient groups only.

Our Team

The CML Advocates Network is run by the elected CML Steering Committeecomposed of six CML patient advocates representing the major regions of the world plus the three co-founders of the network. The management is supported by the Executive Director with our Programme Managers.

- The CML Steering Committee -

FELICE BOMBACI

Co-chairman of the CML Advocates Network.

Chairman of the Gruppo AIL Pazienti Leucemia Mieloide Cronica, Italy.

Region Western Europe Representative

SARUNAS NARBUTAS

Co-chairman of the CML Advocates Network.

Lithuanian Cancer Patient Coalition (POLA).

Region Central and Eastern Europe & West Asia Representative.

JANA PELOUCHOVÁ

Co-founder of the CML Advocates Network.

President of Diagnoza Leukemie, Czech Republic.

GIORA SHARF

Co-founder of the CML Advocates Network.

Director of Flute of Light, Israel.

JAN GEISSLER

Co-founder of the CML Advocates Network.

Chair of LeukaNET, Germany

LISA MACHADO

Treasurer of the CML Advocates Network

Canadian CML Network Executive Director, Canada.

Region North America Representative.

BAHIJA GOUIMI

President of the Association AMAL, Morocco.

Region Middle East & Africa Representative.

JOSÉ CASTRO

Fundraiser, Legal and Scientific Affairs of AGALEMO, Asociación Amalia y Glenn Dewey para Pacientes con Leucemia y Mieloma, Costa Rica.

Region Latin America Representative.

ROD PADUA

President of Touched By Max, Philippines.

Region Asia-Pacific Representative.

- The team -

DENIS COSTELLO

Executive Director of the CML Advocates Network

denis@cmladvocates.net

CELIA MARÍN

Head of Communications and Programme Manager of the CML Advocates Network

celia@cmladvocates.net

LIDIJA PECOVA

Head of Member Relations, Events and Programme Manager of the CML Advocates Network

lidija@cmladvocates.net

Our Audience

Visitors of the website are
- Patient advocates leading leukemia support groups, aiming to get in touch with other national groups, and to share experience in advocacy in the member area
- Patients and their relatives to locate support groups, e.g. in their home country or in other countries
- Health professionals and carers who are interested in key issues of the CML patient community.
The website does not aim to provide information to medical professionals. Hence, the website is provided in plain, patient-friendly language, and is hesitant in using medical terms.

Features for members

Most of the website's content, including news from the network, the CML glossary, the CML trial registry and CML-related information are openly accessible.

The member area is only accessible to registered members and requires a login. A login account can be provided by the moderators of the website after registration. The moderators will then check whether the applicant is representing a leukemia patient organization.

Access to the member-only area is only granted leaders of patient organizations, not to individual patients or non-patient stakeholders. The reason is that the main goal of the network is to link up patient advocates and to facilitate best practice sharing in CML advocacy. However, we invite individual patients to use our website to search for a local patient organization in their country.

The following functionality is available to registered members:
- Discussion forums, with subforums e.g. on advocacy, on how to set up patient websites, what activities the groups have, share their successes and failures that they encounter, so all the others can learn from these experiences, etc.
- Download area for files, e.g. conference material.
Legal disclaimer

The maintainers of this website have no medical qualifications and the information contained on this site is not intended to replace expert medical advice that you may be given. We do our best to ensure that any information we publish is accurate and strongly advise that any decisions about your treatment should be made after discussions with your haematologist or other suitably qualified medical professional.

We are purely patient-run, non-profit and public interest. Talking to each other is always the best solution. Before taking any legal action against us for whatever reason, please contact us - we are very confident we can solve any issue in both interests without the need for any legal steps.

How to contact us

This website - and the CML Advocates Network - is formally hosted by the "Leukemia Patient Advocates Foundation", a global patient-led non-profit foundation registered in Switzerland. The foundation is connecting leukemia patient organizations on all continents to strengthen their advocacy work. Its mission is to improve the lives and survival of patients affected by leukemia as well as their relatives by supporting leaders in providing help and support.

You can get in touch with us at info@cmladvocates.net

You can also use the Contact us website. We're happy to receive your feedback or enquiry!

The formal responsibility of this website belongs to the following organisation:

Leukemia Patient Advocates Foundation
P.O.B. 453
CH-3000 Bern 7
Switzerland

The trustees of the Leukemia Patient Advocates Foundation are Jana Pelouchová (President), Giora Sharf (Treasurer), Jan Geissler (Vice President and Managing Director) and Erik Aerts.

Technology

The website was built on free software and is hosted and maintained on a low-cost basis. This was to make sure the website does not require significant funding after its initial set-up. The website was set up using the Open Source Software Joomla. We would like to thank the enthusiasm of those engaged in Open Source Software. This project would have never been possible without open source projects and their communities!

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
Algeria: Philadelphia LMC

CONTACT INFORMATION:

Mailing/Postal Address:

Cite1600 logements bloc135 appartement 5 khroub

025200 Constantine

Country

Algeria

Tef: 002132699100

Fax: 0021337860227

E-Mail: khaldounwahid@hotmail.com
Web: http://lmcalgeria.blogspot.com

KEY CONTACT:

Mr Khaldoun Wahid, Vice President

BRIEF DESCRIPTION OF ORGANIZATION:

Non-profit organization created in 2013 by and for CML patients what is the first and only CML patient’s association in Algeria.

KEY OBJECTIVES AND KEY INITIATIVES OF ORGANISATION

Our goals

1-Patient’s support

2-Patient’s advocacy

3-Patient’s education

4-Reach the maximum number of patients on a national scale: Make a national project

Number of members or patients organisation represents today

153

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
ASH 2016 update on stopping CML treatment with TKIs in deep molecular response

Tyrosine kinase inhibitors (TKI) have dramatically improved survival of CML and made it a chronic disease. However, life-long therapy is still advised according to expert recommendations and the product labels of current TKI treatments. Depending on the choice of TKI, about 40-70% of CML patients reach a deep molecular response, meaning a BCR-ABL ratio of 0.01% (MR4) or below. Given it had been observed that some patients were able to stop treatment in deep remission without a recurrence of the disease, the effectiveness of stopping TKI treatment of CML patients at large having a sustained, deep molecular response is a key question that is being investigated in various studies, and is probably the most debated CML topic at this year’s ASH.

We are summarizing the most important presentations, discussions and posters on that important topic at the ASH congress this year.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
ASH 2016: Interviews about hot topics in chronic myeloid leukemia

The American Society of Hematology’s annual meeting brings together hematologists from around the world to discuss critical issues in hematology, examines the latest clinical advances in this area and explores the year's most significant scientific discoveries and updates.

Jan Geissler, Co-founder of the CML Advocates Network and chair of the German leukemia patient platform Leukaemie-Online has been interviewed by the Video Journal of Hematological Oncology. during ASH 2016 on some of the hot topics at ASH 2016.

We are happy to share with you these short video interviews that highlight a CML patient’s view on the safety of stopping treatment in Chronic Myeloid Leukemia, the new BCR-ABL inhibitor ABL001 for CML treatment, generic Imatinib in the age of Imatinib patent expiration, patient involvement in th ASH congress, as well as some European programs and initiatives in hematology like HARMONY and the European Reference Network EuroBloodNet.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
ASH 2017- personal report, impressions and summary

- Written by Sharf Giora, CML Advocates Network -

ASH 2017 is the 10th ASH conference I am attending in a raw, and I am being asked many times why do I like this conference and travel such a long distance to attend it every year.

The main reason that I, as a patients representative, leave home and travel to ASH is to hear and learn about the last innovations in the treatment of blood cancers and bring these news to patients in my country and across the globe, to empower them with knowledge, and mainly hope. that research in the various diseases is ongoing and if they are in a need for a new treatment, maybe it is just around the corner. The second reason why I go to ASH, which is not less important, is that this is the best place and opportunity to meet in a short time all the stakeholders that I am working with, like Drs and scientists from Israel and the globe, Pharma representatives from medical and patients relations, and other patients advocates, and to discuss with all of them how to continue and strengthen our collaboration.

- Giora and Nadav, a board member of
Flute of Light at ASH 2017 -
Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
Calling CML Patient Advocate Leaders to apply for the 3rd EUPATI Patient Expert Training Course

THE EUPATI PATIENT EXPERT TRAINING COURSE IS TAILORED TO PATIENT ADVOCATES AND TURNS THEM INTO PATIENT EXPERTS IN MEDICINES RESEARCH AND DEVELOPMENT.

DEADLINE FOR APPLICATIONS IS 31 MARCH 2017

The EUPATI Patient Expert Training Course in Medicines Research & Development is an exciting and unique opportunity, offering patient advocates expert-level training that is specifically tailored for them.

This 14-month tailor-made course, based on e-learning with additional two face-to-face training weeks, gives you the tools as CML patient advocate leaders to be able to contribute to be part of the research and development process and all related regulatory processes. It helps to understand all processes of pre-clinical and clinical research, drug safety, benefit/risk assessment and health technology assessment at an expert level.

So far, three CML advocates members have participated in the EUPATI course: Conny Borowczak, Aimo Stromberg and Sarunas Narbutas. Read about Conny's experience by clicking on "Read more", and contact them if you have questions.

We encourage European patient advocates (from the wider European region as defined by WHO) to apply before the deadline of 31st March at https://www.eupati.eu/third-cycle-apply-now/

Click on read more for Testimonial.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Clinical Trials Registry now lists 35 ongoing studies

Patients wishing to participate in a clinical study often look for a central source of information where they can find easy-to-understand facts on ongoing trials.

Official trial registries like clinicaltrials.gov or other trial registries are available but tend to be complex and difficult to use for patients.

To fill the need for a single source of information on CML studies in plain language, CML Advocates Network set up an unofficial online CML Trials Registryin 2013.

The database contains a brief description of ongoing CML trials initiated by academia (universities) or pharmaceutical companies.

Currently, 24 clinical studies are listed that are actively recruiting patients. Another 11 studies are still ongoing but no longer including new patients.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2017 - Save the date: 26-28 May 2017

Join us for the 15^th “CML Horizons: Learn. Share. Grow" Conference
DATE: 26TH TO 28TH MAY 2017
LOCATION: FRANKFURT, GERMANY

Equip yourself with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy, empower yourself & gain the courage to fight for the rights of CML patients, learn from the experts - both patient advocates and physicians.

This exciting one of its kind conference will enable you to be able to exchange ideas, interact & share best practice. You will also have the opportunity start networking across borders and build alliances and so much more for you to bring back to your own organization.

Registration process will start the 2nd week of January 2017 and will inform you as soon as the registration platform is online.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2017 Registration Now Open - 26-28 May 2017

Register here - Preliminary Program - Conference fee - Scholarship Application
- Call for Abstracts - Call for Posters - Travel - Visas - Venue & Accommodation - Acknowledgements - Call for Nominations

Registration is now open - Join us for the 15^th “CML Horizons: Learn. Share. Grow" Conference

DATE: 26TH TO 28TH MAY 2017
LOCATION: FRANKFURT, GERMANY

Equip yourself with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy, empower yourself & gain the courage to fight for the rights of CML patients, learn from the experts - both patient advocates and physicians.

This exciting one of its kind conference will enable you to be able to exchange ideas, interact & share best practice. You will also have the opportunity start networking across borders and build alliances and so much more for you to bring back to your own organization.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2018 Registration Now Open - 4- 6 May 2018

Register here - Preliminary Program - Conference fee - Scholarship Application
- Call for Poster Presentation Abstracts - Travel - Visas - Venue & Accommodation - Acknowledgements

Registration is now open - Join us for the 16^th “CML Horizons: Learn. Share. Grow" Conference

DATE: 4TH to 6th MAY 2018
LOCATION: WARSAW, POLAND

Equip yourself with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy, empower yourself & gain the courage to fight for the rights of CML patients, learn from the experts - both patient advocates and physicians.

This exciting one of its kind conference will enable you to be able to exchange ideas, interact & share best practice. You will also have the opportunity start networking across borders and build alliances and so much more for you to bring back to your own organization.

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2019 Registration Now Open - 17th to 19th May 2019

Register here - Preliminary Program - Conference fee - Scholarship Application

Call for Poster - Call for Nominations Travel - Visas - Venue & Accommodation - Acknowledgements

Registration is now open - Join us for the 17^th “CML Horizons: Learn. Share. Grow" Conference

DATE: 17th to 19th MAY 2019
LOCATION: Lisbon, Portugal

Due to events beyond our control and with sad regret we have changed the location of this year's Horizons. Even though location has been changed to Lisbon, Portugal this does not take away from why we had chosen Nairobi as our original destination and that is to honour our dearly departed Ferdinand Micho who was a leader in the fight of CML in Africa and the Middle East but also for the challenges that CML patients face in low and middle-income countries in access to treatment and monitoring.

We have secured top speakers from Western countries like Dr. Francois Mahon & Dr. Gianantonio Rosti, also African and Asian countries such as Dr. Qian Jiang from China, Dr. Abinya from Kenya and Dr. Benneh from Ghana. More speakers are expected to confirm soon.

The CML Horizons conference is dedicated to the development of our members as patient advocates and deals with topics such as: - What is the goal of CML Treatment? Improving access, Key initiatives in CML treatment & advocacy and Living with CML and the future outlook. Dealing with these types of questions is the essence of Learn. Share & Grow and our conference offers the opportunity to support and facilitate the quality of education. This one of a kind conference also provides opportunities to be able to exchange ideas, interact & share best practice and provide a platform to start networking across borders, build alliances and so much more for you to bring back to your own organization.

We very much hope that you will be able to attend the 17th conference of its kind - with an exciting program on CML advocacy and CML science.

Our conference will provide you with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy and learn from the experts - both patient advocates and physicians by networking opportunities with CML advocacy leaders around the globe.

CLICK HERE TO REGISTER

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

CML Horizons 2020 Acknowledgements

CML Logotip Costa Rica 2020 1

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

Acknowledgment of Sponsors

We would like to thank the following sponsors for providing unconditional grants - without their support, this conference would not be possible:

Novartis Oncology (Initiating platinum sponsor)
Bristol-Myers Squibb (Gold Sponsor)
Pfizer (Gold Sponsor)
Incyte Biosciences International Sàrl (Gold Sponsor)
Takeda Oncology (Silver Sponsor)
The Leukemia & Lymphoma Society (Bronze Sponsor)
International CML Foundation (Bronze Sponsor)

If you want to support the conference, we would be delighted!

{rscomments off}

Chronic Myeloid Leukemia

also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

BCR-ABL ratio

The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).

Hematologist

A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)

Compliance

Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.

Generics

A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.

Imatinib

Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec

BCR-ABL

The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22

Chronic

Long-lasting, slowly developping

Acute

Of sudden onset, severe; of short duration.

CLL

Chronic lymphocytic leukemia

Gene

A unit of information present as DNA; a gene usually contains the blueprint for a protein.

CML

Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.

ASH

American Society of Hematology

MR4

Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)

CHR

Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.

CML Horizons 2020 Call for Nominations
Register here - Preliminary Program - Conference fee- Scholarship Application

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

Call for nominations for the regions of Asia & Pacific and Latin America of the CML Horizons Steering Committee.

At CML Horizons 2019, the community elected its fifth global "CML Horizons Steering Committee", consisting of CML patient advocates from North America, Middle East and Africa, Western Europe, Latin America, Asia & Pacific and Central and Eastern Europe & West Asia regions.

Our Steering Committee is made up of expert CML Patient Advocates and Is intended to serve as a leading team member for the CML community by providing support and help to implement CML Horizons annual meetings, as well as other projects, led by the CML Advocates Network.

The current term CML Horizons Steering Committee from Asia & Pacific and Latin America is coming to an end at "CML Horizons 2020" in Costa Rica, and hence we would like to ask the community to nominate candidates for the upcoming elections. If you are from these regions, this is your opportunity to become an active and professional CML Patient Advocate and empower yourself as well as your region. If you feel you can contribute, please submit your nomination.

The CML Horizons Steering Committee consists of one elected representative from each of the six major regions:
- Asia & Pacific
- North America
- Latin America
- Middle East & Africa
- Western Europe
- Central and Eastern Europe & West Asia
plus, the three CML Advocates Network founders as permanent committee members.

Deadline for nominations: 15th April 2020

To nominate a candidate for the election of the "CML Horizons Steering Committee 2020-2023", we would like to ask your patient organisation to submit the nomination form by 15th April 2020 to elections@cmladvocates.net

The nomination needs to state your motivation and contribution to the committee on behalf of your region, your history and vision as CML advocate, your English language skills, and whether you are willing to commit significant time for teleconferences, meetings and emails to bring the community and conference to the next level.

Every CML Advocates Network member organisation can nominate only one candidate from their region. A list of CML Advocates Member organisations can be found here: http://www.cmladvocates.net/members

Please look at the nomination form for further information.

Elections

The elections will be held at CML Horizons in San José on Saturday 2nd May during the regional sessions. All nomination files will be provided to all members during the regional sessions, to give everyone sufficient time to consider their vote. In addition, every candidate will present themselves in the first of the two regional sessions planned for 2020.

Every member organisation from Asia & Pacific and Latina America regions of the CML Advocates Network has one vote per seat at the elections. Even if there are 2 delegates from a specific organisation, they have only one vote. Email votes are not permitted. Only those organisations that participate in the conference in San José can take part in the voting.

Questions?

If you have any questions, please feel free to contact Lidija Pecova lidija@cmladvocates.net or Giora Sharf giora1@inter.net.il at any time.

Your CML Steering Committee,
- Giora Sharf (Israel/co-founder CML Advocates Network)
- Jan Geissler (Germany/co-founder CML Advocates Network)
- Jana Pelouchová (Czech Rep./co-founder CML Advocates Network)
- Šarūnas Narbutas (Lithuania/Central and Eastern Europe & West Asia)
- Lisa Machado (Canada/Region North America Representative)
- Bahija Gouimi (Morocco/Region Middle East & Africa Representative.)
- Felice Bombaci (Italy/Region Western Europe Representative)
- José Castro, (Costa Rica/Region Latin America Representative)
- Rod Padua (Philippines/Asia-Pacific)
{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2020 Call for Posters

Register here - Preliminary Program - Conference fee- Scholarship Application

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

Call for Posters: CML Advocacy Poster Area at CML Horizons 2020

What is the CML Advocacy Poster Area?

The CML Advocacy Poster Area is a separate area inside the venue where CML Horizons 2020 participants can display a paper poster illustrating their CML patient advocacy activities, projects, and outcomes.

During CML Horizons 2020 conference, your poster will be shown and accessible by all conference participants and shared throughout our social media channels.

The aim of the Poster Area is to provide participants with the opportunity to share their key activities and learn from the initiatives and experiences of other CML organisations from around the world in CML advocacy.

Win the Best Poster Award!

During the conference, there will be an opportunity to vote (once only per organization) for the best poster and we will announce the winners on Sunday, 3rd May.

So, we invite you to bring your poster to the conference please note that we will not be able to print the poster on spot, so bring your printed posters with you, please.

This is an amazing opportunity to showcase your Organisations’ yearly activity or a special project that made an impact on the CML Community in your country on a worldwide platform and share your activities.

How can I submit a poster?

Participants who would like to display a poster in the CML Advocacy Poster Area are invited to create a poster using the template and recommendations below. Participants can use this poster template or can have their own design.

Be creative!

You can be as creative as you like or you can use our poster guideline and template, we have made for you. You can download this template HERE.

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2020 Conference Fee
Register here - Preliminary Program - Conference fee- Scholarship Application

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

CML Horizons 2020 Conference fee for regular delegates

A conference fee of EUR 500 per delegate will be invoiced to the participant in the name of the Leukemia Patient Advocates Foundation, Switzerland, in advance of the meeting. The conference fee covers
- max 4 – 5 nights of accommodation,
- local transportation from Juan Santamaría International airport to the conference and back.
- food and drinks (breakfast, lunch and dinner), during the conference.
- Free wifi internet in conference rooms, and in bedrooms too.
- the general costs of the conference.
Participants are expected to cover their own travel to Juan Santamaría International airport (e.g. flights). The conference fee does not cover incidental costs like bar, mini-bar, phone calls, taxi costs, upgrades for double rooms, relatives attending the conference, and any other non-official activities.

Payment of the conference fee must arrive before the start of the conference. It must also be paid in case of cancellations no later than 30 days before the conference. The conference fee should be paid by wire transfer to the foundation. Should another postal address be required on the invoice for the conference fee, the delegate must provide a note during the electronic registration process, stating the full postal address and the name of the organization who will pay the conference fee.

For those that cannot find organisations or sponsors to cover the costs to attend the conference, see our Scholarship page

Sponsor delegates participation

Sponsors' delegates are also expected to register at the registration website. Room bookings will then be made by our logistics agency. Pharma representatives are expected to book their own flights and settle their room charge at the hotel. We will organise their individual local transport to the conference venue if they provide us with their flight details at least two weeks before the conference. Costs for attending the conference, including the daily delegate rate and all meals, will be covered by us and will not be invoiced to pharma representatives.

If you have any Questions?

Please contact Lidija Pecova lidija@cmladvocates.net or Giora Sharf giora1@inter.net.il should you need any assistance.

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2020 Preliminary Program

Register here - Preliminary Program - Conference fee- Scholarship Application

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

Preliminary Programme of CML Horizons 2020

Friday 1st to Sunday 3rd May 2020

Faculty - Dr. Hochhaus, Dr. Cortez, Dr. Lipton, also Dr. Benneh.

Overall contact and programme coordination

Please contact Lidija Pecova lidija@cmladvocates.net, Lisa Machado lisa.machado@outlook.com or Giora Sharf giora1@inter.net.il should you need any clarification about the conference programme.

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2020 Registration Now Open

Register here- Preliminary Program - Conference fee - Scholarship Application

Call for Poster - Call for Nominations Travel - Visas- Venue & Accommodation - Acknowledgements

Registration is now open - Join us for the 18th “CML Horizons: Learn. Share. Grow" Conference

DATE: 1st to 3rd MAY 2020 - LOCATION: San José, Costa Rica

For the first time, the 18th CML Horizons will be held outside of Europe and will take us to Central America in beautiful Costa Rica.

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
CML Horizons 2020 registration now open

Registration is now open - Join us for the 18th “CML Horizons: Learn. Share. Grow" Conference

DATE: 6th to 8th NOVEMBER 2020 - LOCATION: Virtual

taking place during the Time Zone of Central European Time (CET).

Due to on-going events surrounding COVID-19 the CML Advocates Network Steering Committee have decided to hold this year’s conference as a virtual event.

As we move online, we look forward to offering you the same vibrant Programme and have secured top medical speakers as Dr. Andreas Hochhaus, Dr. Jeff Lipton and Dr. Jorge Cortes and Doctor Benneh who will speak about the future outlook for CML treatment, the impact of generic medicines as well as updating us on the latest developments in Treatment-Free Remission.

Our advocacy sessions will also take stock of how CML patient groups have adapted to supporting the patient community during COVID-19, access to treatments and how to strengthen advocacy efforts through alliances and partnerships. This year's congress will also feature special messages from Dr. Brian Druker and Dr. Pia Raanani.

CLICK HERE TO REGISTER

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
COVID-19
(Also called Coronavirus or SARS-Cov 2) An infectious disease caused by a newly discovered coronavirus in 2019. Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
TFR
Abbreviation for Treatment-Free Remission. In CML is referred to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment after having been in deep molecular residual disease over a longer period of time.
CML Horizons 2020 Scholarship Application
Register here - Preliminary Program - Conference fee- Scholarship Application

Call for Poster - Call for Nominations Travel- Visas- Venue & Accommodation - Acknowledgements

Application for Scholarship / Conference Grant

We encourage everyone to seek sponsors in during 2019 and early 2020 to cover the travel and conference costs. However, we acknowledge that not everybody is able to find an organisation or sponsor to participate in CML Horizons 2020.

Therefore, a limited number of 40 scholarships, full or partial, are available for patient advocates who are interested in attending the conference and who cannot find sponsors for their attendance. Applications for these scholarships are invited from interested advocates. Those that are granted will receive an economy class return ticket to San José and will not need to pay the conference fee.

Eligibility criteria

To be eligible for a scholarship, candidates should:
- Be a staff member or volunteer of an established CML patient organization that is a member of CML Advocates Network,
- Be in a country where a local sponsor is unavailable to support attendance at the conference OR be an individual who is in the process of setting up a CML patient organization where regulations prohibit local sponsoring his/her attendance at the conference.
- Hold a position where they can shape ongoing advocacy activities and initiate new ones
- Be proficient in English
- Preference will be given to applicants coming from countries with limited resources.
Scholarship types

We are offering two different types of scholarships, which will be given according to the needs of each applicant.
- Full scholarship: This scholarship will cover both the flight costs and an exemption from the conference fee.
- Partial scholarship: This scholarship will cover either the flight costs or the conference fee.
Application procedure

Interested advocates should submit an application with the Attached Application form by 15th March 2020. Please email your application to Vanja at email: cml@balkan-adriatic.com

The CML Horizons Steering Committee members will review and prioritize all applications received. Applicants will be informed whether they will receive a grant and whether it is a full or partial grant, as soon as possible. According to our policy, there is a maximum of 1 scholarship per patients’ organization.

{rscomments off}

Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
BCR-ABL ratio
The BCR-ABL ratio is a quantitative determination of the CML-typical BCR-ABL gen. The number of BCR-ABL “copies” in relation to a control gen which is present in all cells is a measure of disease activity or "tumour burden" of CML. In lab reports, this value is frequently stated in percent, but sometimes also as a "ratio" or "quotient". In general, the control gen "ABL" is used to calculate the quotient, but other genes may also be used (e.g. BCR, GUSB, G6PD).
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Compliance
Willingness of a patient to reliably adhere to treatment measures and follow medical instructions.
Generics
A class of medicinal products where the drug is comparable to a branded product in dosage form, strength, route of administration, quality and efficacy, and intended use. A generic drug can only be marketed after patent exclusivity protection ends.
Imatinib
Imatinib, trade name Glivec/Gleevec, development name STI-571, a first-generation BCR-ABL tyrosine kinase inhibition. Authorized for marketing since 2002 for the treatment of CML and Ph-positive ALL.
Other names: Gleevec|Glivec
COVID-19
(Also called Coronavirus or SARS-Cov 2) An infectious disease caused by a newly discovered coronavirus in 2019. Most people infected with the COVID-19 virus experience mild to moderate respiratory illness and recover without requiring special treatment. Older people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness.
BCR-ABL
The abnormal gene that characterizes Chronic Myeloid Leukemia, which is a fusion of the BCR gene of chromosome 9 and the ABL gene of chromosome 22
Chronic
Long-lasting, slowly developping
Acute
Of sudden onset, severe; of short duration.
CLL
Chronic lymphocytic leukemia
Gene
A unit of information present as DNA; a gene usually contains the blueprint for a protein.
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
ASH
American Society of Hematology
MR4
Molecular response, or molecular remission, with a reduction of 4 log (BCR-ABL <0,01%)
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.
TFR
Abbreviation for Treatment-Free Remission. In CML is referred to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment after having been in deep molecular residual disease over a longer period of time.

Page 1 of 2

Start
Prev
1
2
Next
End